Genmab — August 2018
-
Sorry.
-
Når man tænker på medicinal/ biotek aktier så vil der komme lange perioder hvor der ikke kommer nyt, hvilket i normal term alt andet lige vil medføre sivning af kursen. Genmab har (og er ) været i den trend længe, men det betyder jo ikke at casen er blevet ringere. !! - når der virkelig kommer spark i salget behøves ikke yderligere nyheder før stigning. - Så er ekstra gode nyheder jo bare en bonus. På dette niveau køber jeg op med alt hvad jeg kan spare op til den lidt længere bane. My choice.
-
June:
A pre
-clinical milestone has been reached in the DuoBody collaboration with Novo Nordisk,
triggering a milestone payment to Genmab. In addition, Novo Nordisk has extended exclusivity of
the commercial license for a target pair under this collaboration, tri
ggering a payment to Genmab -
-
What data is expected from Alcyone?
-
No data expected - but approval in EU
-
Sådan kan det gå Henrik. Tak for opfølgningen
-
Alt under 90 % er uacceptabelt
-
Var der noget om det stoppede forsøg?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind